Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022003021 - ADAM17 INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF COVID-19

Publication Number WO/2022/003021
Publication Date 06.01.2022
International Application No. PCT/EP2021/067992
International Filing Date 30.06.2021
IPC
A61K 31/341 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
341not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/451 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
451having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/496 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/54 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
CPC
A61K 2039/5156
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5156expressing foreign proteins
A61K 31/341
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
341not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/451
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
451having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT [DE]/[DE]
Inventors
  • DE LA ROSA, Kathrin
Agents
  • KADOR & PARTNER PART MBB
Priority Data
20183093.230.06.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ADAM17 INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF COVID-19
(FR) INHIBITEURS D'ADAM17 DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉVENTION ET/OU LE TRAITEMENT DE LA COVID-19
Abstract
(EN) The invention relates to an ADAM17 inhibitor for use in the prevention and/or treatment of COVID-19 in a subject. The invention further relates to a pharmaceutical composition comprising an ADAM17 inhibitor as an active ingredient for use in the prevention and/or treatment of COVID-19 in a subject. The invention further relates to a kit of parts for use in the prevention and/or treatment of COVID-19 in a subject comprising i) an ADAM17 inhibitor and ii) a vaccine. The invention further relates to a pharmaceutical composition comprising an ADAM17 inhibitor and an active immunization vaccine. The invention further relates to a kit of parts comprising i) an ADAM17 inhibitor and ii) an active immunization vaccine. The invention further relates to a method of preventing and/or treating COVID- 19 in a subject, in the need thereof.
(FR) L'invention concerne un inhibiteur d'ADAM17 destiné à être utilisé dans la prévention et/ou le traitement de la COVID-19 chez un sujet. L'invention concerne en outre une composition pharmaceutique comprenant un inhibiteur d'ADAM17 en tant que principe actif destiné à être utilisé dans la prévention et/ou le traitement de la COVID-19 chez un sujet. L'invention se rapporte en outre à un nécessaire d'éléments destiné à être utilisé dans la prévention et/ou le traitement de la COVID-19 chez un sujet comprenant i) un inhibiteur d'ADAM17 et ii) un vaccin. L'invention concerne également une composition pharmaceutique comportant un inhibiteur d'ADAM17 et un vaccin d'immunisation active. L'invention concerne en outre un nécessaire d'éléments comprenant i) un inhibiteur d'ADAM 17 et ii) un vaccin d'immunisation active. L'invention concerne en outre un procédé de prévention et/ou de traitement de la COVID-19 chez un sujet en ayant besoin.
Related patent documents
Latest bibliographic data on file with the International Bureau